On April 29, 2024, NKGen Biotech, Inc. closed the transaction. The company amended the terms of the transaction and issued 12% unsecured convertible promissory note for the principal amount of $330,000 and a 12% promissory note in the principal amount of $220,000 for the aggregate gross proceeds of $550,000?. The transaction included participation from FirstFire Global Opportunities Fund LLC managed by FirstFire Capital Management LLC, Meteora Select Trading Opportunities Master, LP managed by Meteora Capital, LLC, Meteora Capital Partners, LP managed by Glazer Capital, LLC, Meteora Strategic Capital, LLC and Sandia Investment Managment LP.